This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dow Closes at New High as Q2 Earnings Season Heats Up
by Mark Vickery
Earnings season only picks up steam in the weeks to come.
Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $101.64, marking a -0.47% move from the previous day.
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
by Debanjana Dey
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
by Zacks Equity Research
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
by Urmimala Biswas
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $105.49, denoting a +0.18% change from the preceding trading day.
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
by Zacks Equity Research
Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.
The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
by Zacks Equity Research
Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine are included in this Analyst Blog.
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Top Analyst Reports for Abbott, BP & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Smith-Midland Corporation (SMID) and Crimson Wine Group, Ltd. (CWGL).
Aurora Cannabis Inc. (ACB) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Aurora Cannabis (ACB) delivered earnings and revenue surprises of 161.11% and 2.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Patterson Cos. (PDCO) Misses Q4 Earnings Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -1.20% and 0.02%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $103.45, signifying a -0.22% move from its prior day's close.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
by Zacks Equity Research
Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
by Zacks Equity Research
Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $105.81, moving -1.56% from the previous trading session.
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Abbott (ABT) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
DexCom (DXCM) Declines on Potential Competition for Stelo (revised)
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
DexCom (DXCM) Declines on Potential Competition for Stelo
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.